Charles Lickfold - Catalent VP Officer
| 0C8 Stock | EUR 59.93 0.29 0.48% |
Insider
Charles Lickfold is VP Officer of Catalent
| Age | 49 |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Charles Lickfold Latest Insider Activity
Tracking and analyzing the buying and selling activities of Charles Lickfold against Catalent stock is an integral part of due diligence when investing in Catalent. Charles Lickfold insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Charles Lickfold over a month ago Disposition of 637 shares by Charles Lickfold of Catalent subject to Rule 16b-3 |
Catalent Management Efficiency
The company has return on total asset (ROA) of 0.041 % which means that it generated a profit of $0.041 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0873 %, meaning that it generated $0.0873 on every $100 dollars invested by stockholders. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Wetteny Joseph | Zoetis Inc | 51 | |
| Gary Hendler | Eisai Co | 57 | |
| Isao Teshirogi | Shionogi Co | 64 | |
| Andrew Plump | Takeda Pharmaceutical | 58 | |
| Sven Dethlefs | Teva Pharmaceutical Industries | 54 | |
| Yosuke Akita | Eisai Co | 58 | |
| Tatsuyuki Yasuno | Eisai Co | 55 | |
| Armin MD | Swedish Orphan Biovitrum | 65 | |
| Constantine Saroukos | Takeda Pharmaceutical | 52 | |
| Yoshimasa Kyokawa | Shionogi Co | N/A | |
| Aidan Murphy | Ipsen SA | 57 | |
| Nadeem Sarwar | Eisai Co | N/A | |
| Yoshihiro Furuya | Shionogi Co | N/A | |
| Mark Sabag | Teva Pharmaceutical Industries | 52 | |
| Takeshi Shiota | Shionogi Co | N/A | |
| Francois Garnier | Ipsen SA | 61 | |
| MD FAAN | Eisai Co | 73 | |
| Anders MD | Swedish Orphan Biovitrum | 67 | |
| Kazuhiro Hatanaka | Shionogi Co | N/A | |
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Haruhiko Hirate | Takeda Pharmaceutical | 66 | |
Management Performance
| Return On Equity | 0.0873 | |||
| Return On Asset | 0.041 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP CFO | ||
| Paul Surdez, VP Relations | ||
| Steven Esq, Corp VP | ||
| Julien Meissonnier, VP Officer | ||
| Karen Santiago, VP Office | ||
| Ricky Hopson, Pres Supply | ||
| Charles Lickfold, VP Officer | ||
| Aristippos Gennadios, President - Softgel Technologies | ||
| John Chiminski, Chairman of the Board and Presidentident, CEO | ||
| Alessandro Maselli, Senior Vice President - Global Operations |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0873 | |||
| Return On Asset | 0.041 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 11.57 B | |||
| Shares Outstanding | 180.09 M | |||
| Shares Owned By Insiders | 0.36 % | |||
| Shares Owned By Institutions | 99.64 % | |||
| Price To Earning | 44.99 X | |||
| Price To Book | 1.76 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Catalent Stock
When determining whether Catalent is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Catalent Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Catalent Stock. Highlighted below are key reports to facilitate an investment decision about Catalent Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Catalent Stock please use our How to Invest in Catalent guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.